

# Tribbles-2 is a novel regulator of inflammatory activation of monocytes

Katalin Eder<sup>1,\*</sup>, Hongtao Guan<sup>1,\*</sup>, Hye Y. Sung<sup>1,\*</sup>, Jon Ward<sup>1</sup>, Adrienn Angyal<sup>2</sup>, Michelle Janas<sup>3</sup>, Gabriella Sarmay<sup>2</sup>, Erno Duda<sup>4</sup>, Martin Turner<sup>3</sup>, Steven K. Dower<sup>1</sup>, Sheila E. Francis<sup>1</sup>, David C. Crossman<sup>1</sup> and Endre Kiss-Toth<sup>1</sup>

<sup>1</sup>Cardiovascular Research Unit, University of Sheffield, Sheffield, UK

<sup>2</sup>Department of Immunology, Lorand Eotvos University, Budapest, Hungary

<sup>3</sup>Babraham Institute, Cambridge, UK

<sup>4</sup>Institute of Biochemistry, Biological Research Centre, Szeged, Hungary

**Keywords:** inflammation, IL-8, MAP kinases, tribbles

## Abstract

**Inflammatory activation of monocytes is an essential part of both innate immune responses and the pathogenesis of conditions such as atherosclerosis. However, the mechanisms which modulate the response of monocytes to inflammatory stimuli are still poorly understood. Here, we report that tribbles-2 (*trb-2*) is a novel regulator of inflammatory activation of monocytes. Down-regulation of *trb-2* levels potentiates LPS-induced IL-8 production via enhanced activation of the extracellular signal-regulated kinase and jun kinase mitogen-activated protein kinase (MAPK) pathways. In keeping with this, the endogenous level of *trb-2* expression in human primary monocytes is inversely correlated to the cell's ability to produce IL-8. We show that *trb-2* is a binding partner and a negative regulator of selected MAPKs. The potential *in vivo* relevance of these findings is highlighted by the observation that modified low-density lipoprotein profoundly down-regulates *trb-2* expression, which may, in turn, significantly contribute to the inflammatory processes in the development of vascular disease. Taken together, our results define *trb-2* as a potent novel regulator of monocyte biology, controlling the activation of these cells.**

## Introduction

The family of tribbles proteins has recently been identified as potent regulators of signal processing in a number of physiological and pathological processes. Of the three vertebrate tribbles, tribbles-2 (*trb-2*) was first described as a gene up-regulated by mitogens in dog thyroid cells (1, 2). Most of the recent data on this gene and its protein product are observational, describing differential expression in prostate cancer (3), autoimmune uveitis (4) and inflammatory conditions (5). Functional studies on *trb-2* have demonstrated its involvement in the progression of mitosis in *Xenopus* embryos and that it is necessary for the normal development of the eye and the neuronal system (6). A role for *trb-2* in cell division is suggested as gene expression is up-regulated in a subset of acute myeloid leukaemias (AML), and retroviral over-expression of *trb-2* induces AML in mice possibly via

enhancing degradation of certain C/EBP protein forms (7, 8). These results are in line with previous work in *Drosophila*, which demonstrated that levels of the fly homologue of C/EBP (*slbo*) are critical for programmed mitosis and that *slbo* turnover is regulated by tribbles (9).

While the potential importance of tribbles is implicated by these reports and other literature, less is known about the molecular mechanism of their action. Members of tribbles family have been reported to interact and modulate the activity of signal transduction pathways, including the phosphoinositide 3-kinase (PI3K)/Akt (10, 11) and the mitogen-activated protein kinase (MAPK) (12, 13) systems. The functional relevance of tribbles-mediated regulation of these pathways has been highlighted by a recent report suggesting that *trb-2* controls adipocyte differentiation (14). We have shown recently

\*These authors contributed equally to this study.

Correspondence to: E. Kiss-Toth, Cardiovascular Research Unit, University of Sheffield, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK; E-mail: e.kiss-toth@sheffield.ac.uk

Received 16 July 2008, accepted 24 September 2008

Transmitting editor: A. Falus

Advance Access publication 24 October 2008

The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press and The Japanese Society for Immunology are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

that *trb-1* regulates the proliferative capacity of vascular smooth muscle cells via action on MAPK pathways and found this gene to be up-regulated in the wall of atherosclerotic arteries (15). These observations prompted us to further investigate the potential involvement of tribbles proteins in cell types, which play a central role in innate immune responses as well as in the chronic inflammatory disease of the vessel wall.

Monocytes play a central role in the initiation of innate inflammatory responses. Once activated by pathogenic stimuli or cytokines, they normally reside at the sites of inflammation, differentiate to macrophages and coordinate local responses via the expression of a range of cytokines and chemokines, which attract and activate other cell types. It is therefore of crucial importance to the physiological resolution of inflammation to have effective control mechanisms in place which control monocyte/macrophage responses. Activation and recruitment of monocytes to the developing lesion of the arterial wall are essential in the progression of atherosclerosis. Once in the lesion, monocytes produce chemokines, such as IL-8 and cytokines, including IL-1, that further perpetuate the local inflammation. Monocytes differentiate into macrophages that can internalize oxidized low-density lipoprotein (oxLDL) particles, leading to their differentiation into foam cells. In addition, binding of modified LDL will itself regulate monocyte function.

Among others, activation of MAPK has been widely reported as a key intracellular signalling network, contributing to inflammatory activation of monocytes, as measured by the production of IL-8 chemokine, for instance (16–18). However, mechanisms for the down-regulation of these pathways are still ill defined. With the recent identification of tribbles proteins as regulators of MAPK activation (12, 13), we set out to investigate the role of tribbles in the inflammatory activation of monocytes. We (5) and others (1, 2, 19–21) have reported that tribbles expression is regulated by a range of stimuli, including stress, mitogens and cytokines, suggesting that control of signalling systems may be achieved through the modulation of expression of tribbles proteins.

We report here that expression of *trb-2* is selectively down-regulated by acetylated low-density lipoprotein (AcLDL). The consequence of reduced *trb-2* expression is the potentiation of IL-8 production both in THP-1 cells and in human primary monocytes. Our results demonstrate that *trb-2* acts via inhibition of extracellular signal-regulated kinase (ERK) and jun kinase (JNK) activation. The molecular action of *trb-2* is at the level of *trb-2*-mitogen activated protein kinase (MAPKK) complexes, MKK7 and MEK1, that are binding partners of this protein in monocyte/macrophages. Further, we show that the kinase-like domain of *trb-2* is sufficient for binding to MAPKKs, as well as to exert its bioactivity. Co-stimulation of THP-1 cells as well as human primary monocytes with LPS and modified low-density lipoprotein (LDL) leads to the enhancement of IL-8 production, probably via down-regulation of *trb-2*. This raises the possibility that regulation of *trb-2* levels could be a novel control mechanism of both physiological and pathological inflammatory activation of monocytes. Putting these observations together, we suggest that *in vivo* modulation of *trb-2* expression may be an important regulatory mechanism in monocyte biology.

## Methods

All the experiments described in this study were performed multiple times ( $N > 2$ ) and representative datasets are shown.

### *Ethics*

The human samples were obtained under the ethical approval granted by the North Sheffield Research Ethics Committee. This study conforms to the principles outlined in the Declaration of Helsinki.

### *Cells*

THP-1 and Raw 264.7 cells were purchased from American Type Culture Collection and maintained in RPMI (Invitrogen, CA, USA) supplemented with 10% FCS (L-glutamine) and penicillin–streptomycin.

### *Plasmid constructs*

*Trb-1* and *trb-2* expression plasmids were generated by using pCDNA3.1(+) (Invitrogen, Paisley, UK) as a backbone. Protein fragment complementation assay (PCA) fusion proteins were constructed as described before (15). To generate *trb-2*DN and -DC-truncated protein expression constructs, amino acid residues 1–60 and 309–343 were deleted by PCR-aided mutagenesis. All constructs have been fully sequence verified.

### *THP-1 transfection with siRNA*

Transfections were performed using Nucleofector (Amaxa, Cologne, Germany) using program U-001 and Cell line Nucleofector Kit V solution (Amaxa). For most experiments,  $1.0 \times 10^6$  cells were used per nucleofection.

siRNA SmartPool against human *trb-2*, MKK4, MKK7 and MEK1 were purchased from Dharmacon (Chicago, IL, USA) and used according to the manufacturer's recommendation.

### *MAPK inhibitor treatment*

MEK1 inhibitor (PD98059), p38 MAPK inhibitor (SB203580) and JNK MAPK inhibitor (SP600125) were purchased from Calbiochem (Gibbstown, NJ, USA) and used 20  $\mu$ M for MEK1 and JNK MAPK inhibitors and 0.2  $\mu$ M for p38 MAPK inhibitor. The cells were treated for 1 h with inhibitors before the LPS treatment.

### *Immunoblot*

Anti-MKK7, Anti-MKK4 and Anti-MEK1 antibodies were purchased from Cell Signalling Technology (Danvers, MA, USA) and used according to the manufacturer's recommendation. Polyclonal antibody against *trb-2* was raised against the N-terminal region of *trb-2* by standard techniques.

### *Protein fragment complementation assay*

To confirm the physical interaction between *trb-2* and MEK1, MKK4 and MKK7 in live monocytes, we used the yellow fluorescent protein (YFP)-based PCA (22, 23). This approach is based on the observation that the interaction of two fusion proteins, expressing the proteins of interest, coupled to the N- or C-terminal portion of EYFP will lead to re-folding of the YFP fragments and will generate a functional fluorophore. Therefore, by using this approach, the interaction of proteins can be visualized in live cells. The PCA plasmids *trb-2*-V2


and MEK1, MKK4/7 -V1 were generated by tagging *trb-2* and MKKs with half of Venus mutant YFP (V1 and V2) as described before (24). The Venus variant of YFP was used in this assay since it provides a higher signal than EYFP. MKKs and Trb-2 were fused to the N-terminal (V1) or to the C-terminal portions of Venus YFP (V2), respectively. The two expression constructs (*trb-2* and one of the MKKs) were co-transfected and the YFP signal was visualized by FACS (Figs 4C and 5A–D) and fluorescent microscopy (Fig. 4E). As controls, proteins expressing a leucine-zipper in fusion with the N- or C-terminal region of Venus protein (*zip-V1* and *Zip-V2*, respectively) were used. When these two proteins are co-expressed, a strong fluorophore is formed. Therefore, we used this construct pair as a positive control. To detect the level of 'background' in this assay arising from unspecific interactions, the combination of *zip-V1* and *trb2-V2* constructs (which are not expected to interact) was co-expressed.

## Results

### *AcLDL reduces trb-2 expression in monocytes*

In order to identify molecular regulators of monocyte responses by modified LDL in the context of inflammation, we first characterized the regulation of *trb-2* expression by AcLDL

and LPS in a monocytic cell line, THP-1 cells. Given the recent reports highlighting an important regulatory function for *trb-2* in myeloid cells (7, 8, 25), we focussed our studies on this member of the trيبbles family. oxLDL and AcLDL share many basic mechanisms of their action, including receptors (although oxLDL may sometimes use additional receptors as well) and signalling pathways (26–28). THP-1 cells were incubated with AcLDL or LPS and expression of *trb-2* was investigated by quantitative real-time PCR (Fig. 1A and B). While AcLDL incubation resulted in a profound down-regulation of *trb-2* expression, LPS-induced activation resulted in a significant but transient down-regulation of *trb-2* expression. Next, we tested whether AcLDL stimulation of THP-1 cells has an impact on inflammatory activation of monocytes, specifically on LPS-induced IL-8 production. Our results show that AcLDL treatment significantly potentiates maximally induced IL-8 production by LPS in these cells (Fig. 1C). AcLDL treatment alone did not induce IL-8 production, ruling out LPS contamination as a source of potentiation in the combined treatment. To validate our findings, the ability of human primary monocytes to produce IL-8 in response to LPS stimulation was similarly assessed. As shown in Fig. 1(D), co-incubation with AcLDL increased the amount of IL-8 produced in response to LPS, similar to that seen in the monocytic cell line, THP-1.



**Fig. 1.** AcLDL and LPS modulates *trb-2* expression and inflammatory activation of monocytes. (A–B) *trb-2* messenger RNA expression was measured in response to AcLDL (A) and LPS ( $100 \text{ ng } \mu\text{l}^{-1}$ ) (B) treatment ( $5 \mu\text{g ml}^{-1}$ ). In order to assess statistical significance, one-way analysis of variance (ANOVA) test with Dunnett's Multiple Comparison Test was performed.  $*P < 0.05$ ,  $**P < 0.01$  (C) The impact of 24 h AcLDL and LPS treatment alone and in combination was studied on IL-8 protein production in THP-1 cells. Cells were lysed and IL-8 levels were quantified by ELISA (R&D Systems). One-way ANOVA with Dunnett's Multiple Comparison Test was performed to analyse the results.  $*P < 0.05$  (D) Responsiveness of primary monocytes from four healthy volunteers was assessed by stimulating cells with LPS or with co-stimulation by LPS and AcLDL. IL-8 levels, in response to LPS alone, were used as a unit for normalization for each donor and values measured in samples with LPS-AcLDL co-stimulation were expressed relative to these. AcLDL treatment alone did not induce the production of IL-8 (data not shown).

*trb-2 expression controls IL-8 production of monocytes*

To examine whether the observed down-regulation of *trb-2* is mechanistically involved in LPS-induced monocyte activation, we reduced *trb-2* levels by transfecting siRNA against *trb-2* and confirmed suppression as measured by *trb-2* RNA (Fig. 2A) and protein expression (Fig. 2B). As a biologically relevant marker of monocyte activation, IL-8 production was induced in siRNA-transfected cells by LPS treatment and measured by ELISA. The results in Fig. 2(C) show that *trb-2*-treated THP-1 cells produced significantly higher levels of IL-8, compared with cells transfected with control siRNA. To further characterize the importance of *trb-2* expression in monocytes, human primary monocytic cells were isolated from blood, stimulated with LPS and IL-8 production was assessed by ELISA. We found that the level of IL-8 inversely correlated to the expression of endogenous *trb-2* in primary monocytes (Fig. 2D).

*Activation of MAPK pathways controls IL-8 production and is modulated by trb-2*


Previous reports have demonstrated that the expression of IL-8 is regulated by MAPK pathways (29–33). In agreement with this, blocking of JNK or MEK1, but not of p38 activity by pharmacological kinase inhibitors, resulted in the inhibition of LPS-induced IL-8 production (Fig. 3A). As the above data indicated a negative role for *trb-2* in IL-8 production, we hypothesized that *trb-2* may exert its effect through reducing MAPK activation. This was tested by comparing JNK and ERK activation in LPS-stimulated THP-1 cells at normal or reduced *trb-2* levels (Fig. 3B). Western blotting analysis

of MAPK phosphorylation levels showed that *trb-2* treatment potentiated LPS-dependent MAPK activation. These observations are compatible with a negative regulatory role for *trb-2* in control of inflammatory activation of specific MAPK pathways.


*Trb-2 modulates IL-8 production via interaction with MAPKs*

Previously, we demonstrated that *tribbles-1* and *-3* proteins interact with MAPKs and regulate their activity (12, 13). The experiments shown above have demonstrated that reduced *Trb-2* levels lead to elevated IL-8 production through enhanced activation of the JNK and ERK pathways. This suggests a similar mechanism of action to *trb-1* and *-3*, for *trb-2*. Therefore, we investigated the interaction of *trb-2* with MKK4/SEK-1, MKK7 and MEK1, known activators of JNK or ERK, respectively. Our results show that all three MAPKs are endogenously expressed in THP-1 cells and that their expression can be inhibited by specific siRNA treatment (Fig. 4A). As expected, down-regulation of levels of these MAPKs by siRNA led to impaired IL-8 production, in response to LPS (Fig. 4B), indicating that all three proteins contribute to the activation of IL-8 expression in these settings.


Next, we investigated whether *trb-2* physically interacts with the above MAPKs in monocytic cells by using protein fragmentation complementation assay (PCA) as described previously (24). *Trb-2* binding to MKK7 and MEK1 but not to MKK4 was detected by FACS analysis (Fig. 4C). As an additional control, the MEK1–*trb-2* complex was also detected in a co-immunoprecipitation system, as shown in Fig. 4(D). Further to the above, *trb-2*/MEK1 and *trb-2*–MKK7 complexes were



**Fig. 2.** Down-regulation of *trb-2* expression leads to increased IL-8 production. (A) The efficiency of *trb-2* knockdown by siRNA was assessed using qRT-PCR [Student's *t*-test was performed to analyse the results.  $**P < 0.01$  (A)] or western blot (B). In both cases,  $\beta$ -actin was used as a housekeeping control. (C) The impact of reduced *trb-2* levels on LPS-induced IL-8 production was measured by ELISA. Student's *t*-test was performed to analyse the results.  $P = 0.041$  (D) Responsiveness of primary monocytes from four healthy volunteers were assessed by stimulating cells with stimulation by LPS. The relative level of IL-8 produced is expressed as fold induction of unstimulated cells. The relationship between the amount of IL-8 produced and *trb-2* expression levels was measured by linear regression. *trb-2* levels were normalized to the  $\beta$ -actin qRT-PCR signal in the same sample.



**Fig. 3.** Trb-2 is an inhibitor of the activation of MAPK pathways in THP-1 cells. (A) The involvement of MAPK pathways in LPS-induced IL-8 production was measured by the use of inhibitors of specific MAPK pathways. (B) THP-1 cells were transfected with control- or trb-2-specific siRNA and the level of activation for MAPKs (ERK and JNK), contributing to IL-8 production, was assayed by western blotting. The images were digitized and the intensity of the signal quantified from at least three independent experiments. pMAPK levels were normalized to  $\beta$ -actin. Two-way analysis of variance was performed to assess statistical significance of the results. phospho-JNK:  $P = 0.0027$ ; phospho-ERK:  $P = 0.0268$ .



**Fig. 4.** Trb-2 interacts with MEK1 and MKK7 but not with MKK4. (A) MEK1, MKK4 and MKK7 are endogenously expressed in THP-1 cells and their protein expression levels can be down-regulated by specific siRNAs (24 h post-transfection). (B) THP-1 cells were transfected with siMAPKK or control siRNA, as indicated, and stimulated by LPS. Production of IL-8 was detected by ELISA. One-way analysis of variance (ANOVA) with Dunnett's Multiple Comparison Test was performed to analyse the results. \* $P < 0.05$ , \*\* $P < 0.01$  (C) Interaction between trb-2 and the above MAPKKs was also investigated in THP-1 cells, using the MAPKK-V1 and trb2-V2 fusion protein expression constructs and analysed by FACS. Abbreviations: Z, zip; T, trb; M, MAPKK. Co-transfection of zip-v1/trb2-V2 pair was used as a negative control and the zip-v1/zip-v2 pair as a positive control. One-way ANOVA with Dunnett's Multiple Comparison Test (with mock) was performed to analyse the results. \* $P < 0.05$ , \*\* $P < 0.01$  (D) Interaction between MEK1 and trb-2 was detected in THP-1 cells by co-immunoprecipitation, which were transfected by trb2-V2 and MEK1 expression constructs. Trb-2 protein was precipitated by anti-GFP antibody and the binding partner was detected by an anti-MEK1 antibody (left lane). As control, total cell lysate was loaded and probed for MEK1 (right lane). Contamination of Ig heavy chain is indicated on the figure (E) Trb-MKK complexes were visualized in Raw264.7 cells. These cells were transfected with the indicated pair of expression vectors, using electroporation, as for the THP-1 cells. pEGFPN2 was used as a control of transfection efficiency and the zip-V1 and zip-2 constructs were co-transfected to as positive controls for PCA in these cells.

visualized by fluorescent microscopy, in the macrophage cell line Raw264.7 cells, by PCA (Fig. 4E). In agreement with the FACS results, no interaction between trb-2 and MKK4 was detected in this assay (data not shown). Thus, we conclude that trb-2 specifically interacts with MEK1 and MKK7 but not with MKK4 in monocyte/macrophage cells.

*The kinase-like domain of trb-2 is necessary for MAPKK binding and for the inhibition of activating protein-1 activation*


Tribbles proteins are comprised of an N-terminal, proline-rich N-terminal domain, a central domain, which is similar to serine-threonine kinases but thought to be catalytically inactive, and a short C-terminal domain of unknown function

(34). We have demonstrated previously that the central kinase-like domain of tribbles-1 is required for its ability to inhibit AP-1 activation, which is a well-characterized target of stress kinases (13). In addition, we showed recently that this domain is sufficient for the formation of *trb-1*-MKK4 complexes (15). However, there are no data available to date to evaluate whether the kinase-like domain is a generic requirement for tribbles action within the protein family. Here, we performed a similar analysis of *trb-2*-MAPKK complexes, using HeLa cells, where we have characterized and validated the biological mechanism of action of tribbles proteins previously (12). First, we expressed full-length or truncated *trb-2* proteins, the latter lacking either the N- or the C-terminal tribbles domains. The ability of these proteins to inhibit activating protein-1 (AP-1) activation was assessed in a luciferase reporter system, where stress kinase pathways, leading to the phosphorylation and thus the activation of AP-1 transcription factor was induced by over-expressed MEKK1 (Stratagene, Pathdetect system). We have also shown previously that AP-1 activation by a range of cytokines is blocked by tribbles-3 in this system, thus validating the biological importance of tribbles activity in this assay. As shown in Fig. 5(A), both truncated *trb-2* versions as well as the full-length


protein inhibited AP-1 activation. In addition, PCA analysis demonstrated that both MEK1 and MKK7 are able to form complexes with the truncated *trb-2* proteins (Fig. 5B). However, we note that the level of PCA signal was reduced when truncated *trb-2* were expressed, suggesting that the terminal regions may contribute to the stability of tribbles-MKK complexes. Experiments testing this hypothesis are currently underway. The specificity of *trb-2*/MAPKK interactions, as detected by PCA, was assessed by FACS (Fig. 5C and D). Co-expression of an increasing amount of 'unlabelled' *trb-2* led to a dose-dependent elimination of the YFP signal both in the *trb-2*/MKK7 (Fig. 5C) and *trb-2*-MEK1 (Fig. 5D) complexes, as detected by FACS. In addition, neither MKK-Venus nor *trb-2*-Venus fusion proteins interacted with their zip-Venus counterparts (these were used as positive control constructs in the system), which further supports the specific nature of this interaction.

## Discussion

Appreciation of the molecular events occurring in response to signalling through pattern recognition receptors within monocytes is essential to understanding innate immunity, as



**Fig. 5.** *Trb-2* kinase-like domain is required for inhibiting AP-1 activation and binding to MKKs. (A) The ability of wild-type *trb-2* and truncated protein forms, lacking either the N- or the C-terminal protein domain, to inhibit MEKK1-induced AP-1 activation was measured in a luciferase assay system, using HeLa cells as a test system, as before (12, 13). As a control for inhibition of AP-1 activation, wild-type *trb-1* protein expression construct was used. (B) The capacity of *trb-2* proteins, lacking the N- or C-terminal protein domains, was assessed by PCA, as above. MEK1 and MKK7 were expressed in fusion with the N-terminal V1 fragment of YFP; full-length and mutant *trb-2* was fused to the C-terminal V2 fragment, as previously. (C) (D) FACS was used to show the specificity of interaction between *trb-2* and MEK1 and MKK7. Three doses of untagged *trb-2* expression plasmid (relative to the amount of *trb-2*-V2) were co-transfected (1/10, 1/1 and 10/1) with the above PCA constructs and the mean fluorescence intensity was calculated in the varying samples. One-way analysis of variance with Dunnett's Multiple Comparison Test (with no untagged *trb-2* transfected) was performed to analyse the results. \*\* $P < 0.01$ .



**Fig. 6.** A model for the role of trb-2 in monocyte biology in inflammatory settings. (A) AcLDL uptake by monocytes triggers reduction of trb-2 expression, resulting in a hypersensitive state towards inflammatory stimuli, as exemplified by LPS-induced IL-8 production. (B) The molecular basis of trb-2 regulatory function of MAPKK pathways in the expression of IL-8.

well as conditions when these pathways and processes are subverted in disease pathogenesis. The data presented here illuminate the role of trb-2, a novel, negative regulator of MAPK signalling in the context of LPS stimulation of monocytes. AcLDL, which signals in a manner similar to oxLDL, down-regulates the expression of trb-2. This, in turn, leads to enhanced IL-8 production in LPS-stimulated monocyte cells. Data in other systems have revealed the capacity for tribbles proteins to interact with a range of cell signalling pathways, including members of the MAPK and PI3K network and a number of transcription factors [reviewed in (34, 35)]. We show here that IL-8 expression is controlled by specific MAPK pathways, as demonstrated by pharmacological inhibition of the ERK and JNK pathways and by siRNA-mediated suppression of MEK1 and MKK4, MKK7 expression, respectively. In line with the proposed inhibitory action of trb-2, siRNA-mediated down-regulation of trb-2 expression leads to a significant increase in JNK and ERK activation. Our experiments investigating physical interaction between proteins have shown that trb-2 can interact with MKK7 or MEK1, activators of ERK and JNK. These data indicate that trb-2 is an important negative regulator of monocyte IL-8 production in response to LPS and controls the augmentation of this response by AcLDL (Fig. 6A and B).

We have shown that trb-2 comes into close physical proximity with MEK1 and MKK7 but not MKK4. This is in keeping with the findings of others which support the mechanism of action of tribbles through physical interaction with other signal transduction proteins. This has led to their description as scaffold/regulatory proteins. Our current observations are in strong support of this model. However, molecular details of tribbles/MAPKK interactions and the detailed mode of tribbles action on activation of kinase cascades remain to be determined. It is also noteworthy that trb-2 has been reported to be expressed primarily in the cytoplasm, while trb-1 and -3 are believed to be nuclear proteins (13, 34). Currently, there are no published data on the nature and rel-

evance of interaction between MAPK pathways and trb-2. We suggest that the basic molecular mechanisms responsible for tribbles action are similar for trb-2 to those we have reported to trb-1 previously (12, 15). We have carried out preliminary analysis to characterize the domains of trb-2 protein necessary for the observed MAPK inhibitory activity and investigated, whether the domain minimally required for the inhibition of MAPK activation is also sufficient for the formation of MAPKK-trb-2 complexes. Our data demonstrate that the trb-2 kinase-like domain is sufficient for both activities. These results are in line with our previous reports on trb-1.

The experiments in this study provide evidence that tribbles, a novel group of proteins, can act as regulators of innate immune responses in monocytes. Modulation of such key components may be particularly attractive to pharmacotherapy as the predicted outcome of trb-2 up-regulation (or prevention of down-regulation) would be to reduce innate immune responsiveness without its total abolition. Based on this, we believe that further studies exploring the regulation of tribbles expression in inflammatory disease are warranted to determine whether inhibition of tribbles expression occurs in these conditions.

### Funding

British Heart Foundation project grants (PG/02/122, PG/05/100); Short Term Visiting Fellowship of European Federation of Immunological Societies to K.E.

### Acknowledgements

The authors thank Prof. Stephen Michnick for the Venus PCA constructs.

### Abbreviations

AcLDL	acetylated low-density lipoprotein
AML	acute myeloid leukaemias
AP-1	activating protein-1

ERK	extracellular signal-regulated kinase
JNK	jun kinase
LDL	low-density lipoprotein
MAPK	mitogen-activated protein kinase
oxLDL	oxidized low-density lipoprotein
PCA	protein fragment complementation assay
PI3K	phosphoinositide 3-kinase
trb-1(2)	tribbles-1(2)
YFP	yellow fluorescent protein

## References

- Wilkin, F., Suarez-Huerta, N., Robaye, B. *et al.* 1997. Characterization of a phosphoprotein whose mRNA is regulated by the mitogenic pathways in dog thyroid cells. *Eur. J. Biochem.* 248:660.
- Wilkin, F., Savonet, V., Radulescu, A., Petermans, J., Dumont, J. E. and Maenhaut, C. 1996. Identification and characterization of novel genes modulated in the thyroid of dogs treated with methimazole and propylthiouracil. *J. Biol. Chem.* 271:28451.
- Bisoffi, M., Klima, I., Gresko, E. *et al.* 2004. Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955. *J. Urol.* 172:1145.
- Zhang, Y., Davis, J. L. and Li, W. 2005. Identification of tribbles homolog 2 as an autoantigen in autoimmune uveitis by phage display. *Mol. Immunol.* 42:1275.
- Sung, H. Y., Francis, S. E., Crossman, D. C. and Kiss-Toth, E. 2006. Regulation of expression and signalling modulator function of mammalian tribbles is cell-type specific. *Immunol. Lett.* 104:171.
- Saka, Y. and Smith, J. C. 2004. A *Xenopus* tribbles orthologue is required for the progression of mitosis and for development of the nervous system. *Dev. Biol.* 273:210.
- Keeshan, K., He, Y., Wouters, B. J. *et al.* 2006. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. *Cancer Cell* 10:401.
- Keeshan, K., Shestova, O., Ussin, L. and Pear, W. S. 2008. Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia. *Blood Cells Mol. Dis.* 40:119.
- Rorth, P., Szabo, K. and Texido, G. 2000. The level of C/EBP protein is critical for cell migration during *Drosophila* oogenesis and is tightly controlled by regulated degradation. *Mol. Cell* 6:23.
- lynedjian, P. B. 2004. Lack of evidence for a role of TRB3/NIPK as inhibitor of PKB-mediated insulin signaling in primary hepatocytes. *Biochem. J.* 386:113.
- Du, K., Herzig, S., Kulkarni, R. N. and Montminy, M. 2003. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. *Science* 300:1574.
- Kiss-Toth, E., Bagstaff, S. M., Sung, H. Y. *et al.* 2004. Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. *J. Biol. Chem.* 279:42703.
- Kiss-Toth, E., Wyllie, D. H., Holland, K. *et al.* 2006. Functional mapping and identification of novel regulators for the Toll/interleukin-1 signalling network by transcription expression cloning. *Cell. Signal.* 18:202.
- Naiki, T., Saijou, E., Miyaoka, Y., Sekine, K. and Miyajima, A. 2007. TRB2, a mouse tribbles ortholog, suppresses adipocyte differentiation by inhibiting AKT and C/EBPbeta. *J. Biol. Chem.* 282:24075.
- Sung, H. Y., Guan, H., Czibula, A. *et al.* 2007. Human tribbles-1 controls proliferation and chemotaxis of smooth muscle cells via MAPK signaling pathways. *J. Biol. Chem.* 282:18379.
- Giri, R. K., Selvaraj, S. K. and Kalra, V. K. 2003. Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. *J. Immunol.* 170:5281.
- Hoffmann, E., Dittrich-Breiholz, O., Holtmann, H. and Kracht, M. 2002. Multiple control of interleukin-8 gene expression. *J. Leukoc. Biol.* 72:847.
- Marie, C., Roman-Roman, S. and Rawadi, G. 1999. Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or *Mycoplasma fermentans* membrane lipoproteins. *Infect. Immun.* 67:688.
- Ohoka, N., Yoshii, S., Hattori, T., Onozaki, K. and Hayashi, H. 2005. TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. *EMBO J.* 24:1243.
- Corcoran, C. A., Luo, X., He, Q., Jiang, C., Huang, Y. and Sheikh, M. S. 2005. Genotoxic and endoplasmic reticulum stresses differentially regulate TRB3 expression. *Cancer Biol. Ther.* 4:1063.
- Schwarzer, R., Dames, S., Tondera, D., Klippel, A. and Kaufmann, J. 2005. TRB3 is a PI 3-kinase dependent indicator for nutrient starvation. *Cell. Signal.* 18:899.
- Nyfele, B., Michnick, S. W. and Hauri, H. P. 2005. Capturing protein interactions in the secretory pathway of living cells. *Proc. Natl Acad. Sci. USA* 102:6350.
- Remy, I. and Michnick, S. W. 2004. Mapping biochemical networks with protein-fragment complementation assays. *Methods Mol. Biol.* 261:411.
- Remy, I. and Michnick, S. W. 2004. A cDNA library functional screening strategy based on fluorescent protein complementation assays to identify novel components of signaling pathways. *Methods* 32:381.
- Argiropoulos, B., Palmqvist, L., Yung, E. *et al.* 2008. Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. *Exp. Hematol.* 36:845.
- Van Berkel, T. J., De Rijke, Y. B. and Kruijt, J. K. 1991. Different fate *in vivo* of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. *J. Biol. Chem.* 266:2282.
- Kamps, J. A., Kruijt, J. K., Kuiper, J. and van Berkel, T. J. 1992. Characterization of the interaction of acetylated LDL and oxidatively modified LDL with human liver parenchymal and Kupffer cells in culture. *Arterioscler. Thromb.* 12:1079.
- Yancey, P. G., Miles, S., Schwegel, J. and Jerome, W. G. 2002. Uptake and trafficking of mildly oxidized LDL and acetylated LDL in THP-1 cells does not explain the differences in lysosomal metabolism of these two lipoproteins. *Microsc. Microanal.* 8:81.
- Bhattacharyya, A., Pathak, S., Datta, S., Chattopadhyay, S., Basu, J. and Kundu, M. 2002. Mitogen-activated protein kinases and nuclear factor-kappaB regulate *Helicobacter pylori*-mediated interleukin-8 release from macrophages. *Biochem. J.* 368:121.
- Dobrev, I., Waeber, G., James, R. W. and Widmann, C. 2006. Interleukin-8 secretion by fibroblasts induced by low density lipoproteins is p38 MAPK-dependent and leads to cell spreading and wound closure. *J. Biol. Chem.* 281:199.
- Fu, Y., Luo, N. and Lopes-Virella, M. F. 2002. Upregulation of interleukin-8 expression by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages. *Atherosclerosis* 160:11.
- Kibayashi, E., Urakaze, M., Kobashi, C. *et al.* 2005. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. *Clin. Sci. (Lond)*. 108:515.
- Scholz, H., Yndestad, A., Damas, J. K. *et al.* 2003. 8-Isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases. *Cardiovasc. Res.* 59:945.
- Hegedus, Z., Czibula, A. and Kiss-Toth, E. 2007. Tribbles: a family of kinase-like proteins with potent signalling regulatory function. *Cell. Signal.* 19:238.
- Hegedus, Z., Czibula, A. and Kiss-Toth, E. 2006. Tribbles: novel regulators of cell function; evolutionary aspects. *Cell. Mol. Life Sci.* 63:1632.